Quote:

---

Ohm. When you get a chance. Take a look at Aviceda Therapeutics. They are currently working on the eye but their AVD 104 siglec drug claims to alter macrophage microglia differentiation to the less inflammatory and antifibrotic state. Seems like leronlimab has a broader mechanism of action but they are considering looking a liver disease, cancer, neurodegenerative disease as well.

---

AVD-104 switches macrophages to an M2 (anti-inflammatory) state the opposite of what leronlimab does. This would lead to immunosuppression but what is needed is balance. With highly reduced M2 macrophages it would lead to cancer cells not being killed and aberrant cells in liver and neurodegenerative diseases not being cleared. Leronlimab increases M1 killer cells while lowering cytokines responsible for inflammation.